

**DRUG DISCOVERY TODAY****Editorial**

**Editor:** Steve Carney  
**Senior Editor:** Ulrike Knies-Bamforth  
**Acting Senior Editor:** Sian Bithell  
**Content Development Manager:** Jacky Smith  
**Publisher:** Jaap van Harten  
**Editorial Enquiries:**  
*Drug Discovery Today*  
 Elsevier  
 32 Jamestown Road, London, NW1 7BY, UK  
 Tel: +44 (0)20 7424 4200  
 Fax: +44 (0)20 7424 4314  
 Email: ddt@drugdiscoverytoday.com

**ADVISORY EDITORIAL BOARD**

**Jürgen Bajorath** *University of Bonn, Germany*  
**Walter Blackstock** *Experimental Therapeutics Centre, Singapore*  
**David Brayden** *University College Dublin, Ireland*  
**Paul Caron** *Vertex Pharmaceuticals, USA*  
**David Cavalla** *Arachnova, UK*  
**David Clark** *Argenta Discovery, UK*  
**Dalia Cohen** *Rosetta Genomics, USA*  
**Donald Daley** *Argenta Discovery, UK*  
**Sean Ekins** *ACT LLC and Collaborations in Chemistry, USA*  
**Hans-Peter Fischer** *GeneData, Switzerland*  
**Peter Ghazal** *University of Edinburgh, UK*  
**Christopher M. Hill** *Organon, UK*  
**Nick Hird** *Takeda Chemical Industries, Japan*  
**Enoch Huang** *Pfizer, USA*  
**Thomas Joos** *University of Tuebingen, Germany*  
**Vincent H.L. Lee** *Chinese University of Hong Kong, Hong Kong*  
**David Lewin** *Yale University, USA*  
**Christopher A. Lipinski** *Melior Discovery, USA*  
**Lorenz Mayr** *Novartis, Switzerland*  
**Nick Meanwell** *Bristol-Myers Squibb, USA*  
**Mark Murcko** *Vertex Pharmaceuticals, USA*  
**Fajun Nan** *Shanghai Institute of Materia Medica, China*  
**Gitte Neubauer** *Cellzome, Germany*  
**Eric Neumann** *Teranode, USA*  
**Tim Peakman** *UK Biobank, UK*  
**Norton Peet** *Aurigene, USA*  
**Manuel Peitsch** *Novartis, Switzerland*  
**Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA*  
**Janice Reichert** *Tufts Center for the Study of Drug Development, USA*  
**John Reidhaar-Olson** *Hoffmann-La Roche, USA*  
**Mike Romanos** *GlaxoSmithKline, UK*  
**Raymond C. Rowe** *Intelligensys, UK*  
**Andreas Russ** *University of Oxford, UK*  
**Esther Schmid** *Pfizer, UK*  
**Jonathan Sheldon** *Inforsense, UK*  
**Michael Snyder** *Yale University, USA*  
**Susie Stephens** *Eli Lilly and Co. Ltd., USA*  
**Robert Strausberg** *The J. Craig Venter Institute, USA*  
**Donny Strosberg** *Scipps Florida, USA*  
**Yuichi Sugiyama** *University of Tokyo, Japan*  
**David Szymkowski** *Xencor, USA*  
**Nick Terrett** *Ensemble Discovery, USA*  
**Vladimir Torchilin** *Northeastern University, Boston, USA*  
**Mark Whittaker** *Evotec OAI, UK*  
**Hans Winkler** *Johnson and Johnson, Belgium*  
**Limsoon Wong** *Laboratories for Information Technology (LIT), Singapore*  
**X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

# DRUG DISCOVERY TODAY

**EDITORIAL****555 Managing freedom: Managing researchers as if they were warriors**

*Joost Uitdehaag*

**MONITOR****MOLECULES****633 Application of technologies and parallel chemistry for the generation of actives against biological targets**

*Paul Edwards*

**635 DIARY**

## FORTHCOMING ARTICLES:

**Relaxin family peptide receptors – from orphans to therapeutic targets**

*by Emma T. van der Westhuizen, Michelle L. Halls, Chrisan S. Samuel, Ross A.D. Bathgate, Elaine N. Unemori, Steven W. Sutton and Roger J. Summers*

**DARPinS: A new generation of protein therapeutics**

*by Michael T. Stumpp, H. Kaspar Binz, Patrick Amstutz*

**An early history of the molecular modeling industry**

*by Allen B. Richon*

**Increasing the reliability of the protein interactome**

*by Hon Nian Chua and Limsoon Wong*